You are using an outdated browser. Please upgrade your browser to improve your experience and security.

Quick facts about treatment with VYXEOS for sAML

Learn key facts, statistics, and benefits of treatment with VYXEOS (vix-e-ose).



Induction and consolidation with VYXEOS


In a clinical trial including older adults with t-AML or AML-MRC in which 153 people received VYXEOS and 156 people received the standard chemotherapya treatment for sAML

icon icon

Approximately half of the patients treated with VYXEOS were alive at 9.6 months compared to 5.9 months for those treated with standard chemotherapy.a

icon icon

Estimated survival at 1 year after the start of treatment was 42% for patients treated with VYXEOS compared to 28% for patients treated with standard chemotherapy.a


VYXEOS is an intravenous (IV) chemotherapy used for the treatment of adults and pediatric patients 1 year and older with certain types of newly-diagnosed secondary acute myeloid leukemia (sAML): therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC).


Important Safety Information

VYXEOS has different dosage recommendations from other medications that contain daunorubicin and/or cytarabine. Do not substitute VYXEOS for other daunorubicin and/or cytarabine-containing products.